5 Stocks Dominating Today’s Market Surge

Page 5 of 5

1. Apellis Pharmaceuticals Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals climbed to a new two-year high on Tuesday, as investors gobbled up shares following news that it was set to be acquired by Biogen Inc. at a 140-percent upside.

In intra-day trading, the stock soared to its highest price of $40.45 before trimming a few cents to finish the day just up by 135.40 percent at $40.23 apiece.

In a statement, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) said that it entered into a definitive agreement with Biogen for the latter’s acquisition of its shares at a price of $41 apiece, for a total of $5.6 billion.

On top of the acquisition price, shareholders would likewise receive $2 in cash for every share held, contingent on the achievement of certain annual global sales for Syfovre.

“This transaction represents a compelling outcome for our shareholders and a strong validation of our strategy, scientific innovation, and execution,” Apellis Pharmaceuticals Inc. (NASDAQ:APLS) CEO Cedric Francois said.

“With Biogen’s extensive experience with immunology and rare disease, we believe this transaction will accelerate our impact and enable us to reach more patients,” he added.

The transaction is expected to be closed in the second quarter of the year, subject to customary closing conditions, including regulatory approvals. It is expected to add immediate sales revenue to Biogen, with Apellis Pharmaceuticals Inc.’s (NASDAQ:APLS) Syfovre and Empaveli having achieved combined net sales of $689 million in 2025.

While we acknowledge the potential of APLS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than APLS and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.

Page 5 of 5